Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ announces ARRA grant programs

This article was originally published in The Gray Sheet

Executive Summary

Agency for Healthcare Research and Quality announces two HHS funding opportunities Sept. 25 for comparative effectiveness research supported through the American Recovery and Reinvestment Act of 2009 (1"The Gray Sheet" Aug. 10, 2009). Under the Clinical and Health Outcomes Initiative in Comparative Effectiveness (CHOICE) grants (RO1), AHRQ plans to provide up to a total of $100 million to up to 10 awardees. For the Innovative Adaptation and Dissemination of AHRQ Comparative Effectiveness Research Products (iADAPT) grants (R18), AHRQ plans to distribute $29.5 million among 20 to 25 awardees. The CHOICE program seeks applications for research aimed at generating new knowledge to help inform decision-making in priority areas of clinical care, while the iADAPT program looks for new ways to adapt content and delivery mechanisms of the agency's comparative effectiveness research summary guides, especially for underserved patient and consumer populations. Applications are due Dec. 16

You may also be interested in...



AHRQ, NIH Report To Congress On Comparative Effectiveness Spending Plans

Two Health and Human Services agencies will allocate about $250 million this year in comparative effectiveness research funds from the federal stimulus package; the remainder of the $1.1 billion comparative effectiveness money will be put to use in 2010

ECHA Deliberates On Final Microplastic Proposal As Beauty Industry’s Fate Hangs In Balance

A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.

QUOTED. 2 December. Laurent Faracci.

Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.

Topics

UsernamePublicRestriction

Register

OM004514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel